<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00681967</url>
  </required_header>
  <id_info>
    <org_study_id>1839IL/0525</org_study_id>
    <nct_id>NCT00681967</nct_id>
  </id_info>
  <brief_title>Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head &amp; Neck Cancer</brief_title>
  <acronym>IRESSA&amp;H&amp;N</acronym>
  <official_title>Conventional Postoperative Radiotherapy (Standard Fractionation) Plus Iressa or Hyperfractionated Radiotherapy Plus Cisplatin and Iressa for Advanced Head &amp; Neck Cancer: A Phase I Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation
      radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and
      Iressa
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Both cohorts overall survival (OS) local control (LC) rate at six months and at one year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1 only time-to-recurrence (TTR)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2 only time-to-progression (TTP). Complete Response (CR) rate time to treatment failure (TTF)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>post operative combination of gefinib and RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of gefitinib with RT and Chemotherapy in non operated patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>250 mg; oral</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>IRESSA (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>250mg; oral</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>IRESSA (TM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age over 18 years

          -  Histologically proven squamous cell cancer of the head &amp; neck (SCCHN)

          -  Indication for postoperative Radiotherapy: pT3, pT4, pN2b, pN2c, pN3

        Exclusion Criteria:

          -  Hypersensitivity to ZD1839 or any of the excipients of this product

          -  Tumour stage M1

          -  Co-existing malignancies diagnosed within the last 5 years. Exceptions: basal cell
             carcinoma, cervical cancer in situ

          -  Absolute neutrophil counts &lt;1.5 x 109
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Rochlitz, Prof Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Basel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madeleine Billeter, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca AG, Grafenau 10; 6300 Zug; Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Verena Renggli</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca AG, Grafenau 10; 6300 Zug; Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2008</study_first_submitted>
  <study_first_submitted_qc>May 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2008</study_first_posted>
  <last_update_submitted>September 21, 2010</last_update_submitted>
  <last_update_submitted_qc>September 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. med. Dirk Schneider</name_title>
    <organization>AstraZeneca AG Switzerland</organization>
  </responsible_party>
  <keyword>squamous cell cancer of the head &amp; neck</keyword>
  <keyword>Gefitinib</keyword>
  <keyword>IRESSA</keyword>
  <keyword>EGFR Inhibitor</keyword>
  <keyword>EGFR-tyrosine kinase inhibitor</keyword>
  <keyword>Subjects with histologically proven squamous cell cancer of the head &amp; neck</keyword>
  <keyword>Cohort 1:qualifying for postoperative radiotherapy</keyword>
  <keyword>(pT3, pT4, pN2b, pN2c, pN3).</keyword>
  <keyword>Cohort 2:qualifying for definite chemoradiotherapy</keyword>
  <keyword>(Lateral oropharynx, tonsils: T1N2b-3, T2N1-3, T3any N;</keyword>
  <keyword>Base of tongue, vallecula: T1N1-3, T2-4 any N; Oral cavity,</keyword>
  <keyword>glottic and supraglottic larynx; Any TN1-3, T3-4 any N;</keyword>
  <keyword>Hypopharynx: T1N1-3, T2-4 and N)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

